Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 797,900 shares, an increase of 1,280.4% from the January 31st total of 57,800 shares. Based on an average daily volume of 764,400 shares, the short-interest ratio is presently 1.0 days. Currently, 2.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Achilles Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ACHL. BML Capital Management LLC grew its holdings in Achilles Therapeutics by 555.8% during the third quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after purchasing an additional 3,474,828 shares during the period. XTX Topco Ltd purchased a new stake in shares of Achilles Therapeutics during the fourth quarter worth $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Achilles Therapeutics during the fourth quarter worth $57,000. Two Sigma Investments LP lifted its position in shares of Achilles Therapeutics by 190.1% during the fourth quarter. Two Sigma Investments LP now owns 61,637 shares of the company’s stock worth $70,000 after acquiring an additional 40,388 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in shares of Achilles Therapeutics by 52.7% during the fourth quarter. Two Sigma Advisers LP now owns 34,200 shares of the company’s stock worth $39,000 after acquiring an additional 11,800 shares in the last quarter. 56.38% of the stock is owned by institutional investors.

Achilles Therapeutics Trading Up 0.7 %

Shares of NASDAQ ACHL opened at $1.39 on Friday. The stock has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $1.03. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The firm has a market cap of $57.13 million, a price-to-earnings ratio of -0.84 and a beta of 1.32.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.